Research graph
References from YOSEMITE and RHINE. Local targets link to admitted publications; unresolved targets remain external evidence.
Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies
10.1016/j.ophtha.2015.06.017 · 2015 · External reference
Diabetic retinopathy Preferred Practice Pattern®
10.1016/j.ophtha.2019.09.025 · 2020 · External reference
Intravitreal aflibercept for diabetic macular edema
10.1016/j.ophtha.2014.05.006 · 2014 · External reference
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema
10.1016/j.ophtha.2011.01.031 · 2011 · External reference
Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)
10.1159/000458539 · 2017 · External reference
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
10.1056/nejmoa1414264 · 2015 · External reference
Treatment patterns for diabetic macular edema: an Intelligent Research in Sight (IRIS®) Registry analysis
10.1016/j.ophtha.2019.10.019 · 2020 · External reference
Real-world outcomes of anti–vascular endothelial growth factor therapy in diabetic macular edema in the United States
10.1016/j.oret.2018.06.004 · 2018 · External reference
Clinical outcomes of a treat and extend regimen with intravitreal aflibercept injections in patients with diabetic macular edema: experience in clinical practice
10.1007/s40123-019-00224-x · 2020 · External reference
Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations
10.1097/iae.0000000000000627 · 2015 · External reference
Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema: TREX-DME 1 year outcomes
10.1016/j.ophtha.2016.09.021 · 2017 · External reference
Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
10.1136/bjophthalmol-2015-307249 · 2016 · External reference
Unresolved reference
2021 · External reference
Unresolved reference
2015 · External reference
Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial
10.1016/j.ophtha.2019.03.023 · 2019 · External reference
Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial
10.1001/jamaophthalmol.2020.2685 · 2020 · External reference
Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature
10.1136/bjophthalmol-2016-308388 · 2016 · External reference
Intersession repeatability of visual acuity, colour vision, contrast sensitivity, retinal sensitivity thresholds and retinal thickness in mild diabetic retinopathy
2011 · External reference
Intersession repeatability of visual acuity scores in age-related macular degeneration
10.1167/iovs.08-1935 · 2008 · External reference
Computerized repeating and averaging improve the test-retest variability of ETDRS visual acuity measurements: implications for sensitivity and specificity
10.1167/iovs.11-7797 · 2011 · External reference
Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests
10.1002/bimj.201000239 · 2011 · External reference
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
10.15252/emmm.201505889 · 2016 · External reference
Unresolved reference
2019 · External reference
Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial
10.1001/jamaophthalmol.2020.2699 · 2020 · External reference
Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
10.2147/opth.s100168 · 2016 · External reference
Burden of treatment among patients undergoing intravitreal injections for diabetic macular oedema in Australia
10.2147/dmso.s214098 · 2019 · External reference
Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes
10.1136/bjophthalmol-2020-315933 · 2021 · External reference
One-year results of treatment of diabetic macular edema with aflibercept using the treat-and-extend dosing regimen: the VIBIM study
10.1159/000504753 · 2020 · External reference
Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema
10.1038/s41598-020-78954-3 · 2020 · External reference
Vision outcomes following anti–vascular endothelial growth factor treatment of diabetic macular edema in clinical practice
10.1016/j.ajo.2018.04.010 · 2018 · External reference
Management and outcomes for neovascular age-related macular degeneration: analysis of United States electronic health records
10.1016/j.ophtha.2020.02.027 · 2020 · External reference
